Biomerica Inc (BMRA) Q2 2026 Earnings Report

Biomerica reported its QQ2 2026 results with modest top-line activity and a continued negative bottom line. Revenue reached $1.21 million, down 33% year-over-year and 12% quarter-over-quarter, while gross profit was only $51 thousand for a gross margin of 4.2%. The company posted an operating loss of $1.37 million and a net loss of $1.32 million, translating to an attributed EPS of -$0.45 for the quarter. Operating cash flow was negative at approximately -$0.99 million, contributing to a free cash flow burn of about -$0.95 million and leaving around $2.54 million in cash at quarter-end. Cumulative losses have left a sizable deficit on retained earnings, though the balance sheet remains modestly levered with a current ratio above 3x and a cash position that provides near-term liquidity optionality.

Looking forward, Biomerica faces a challenging near-term earnings trajectory absent a meaningful uplift in demand or a favorable product mix. The company’s pipeline—most notably InFoods and Helicobacter pylori diagnostic offerings—offers potential upside should regulatory approvals, adoption, or partner-driven scaling materialize. However, with a low gross margin, limited revenue base, and ongoing cash burn, the path to profitability hinges on a combination of improving product mix, cost discipline, and external partnerships or licensing opportunities. Investors should monitor quarterly revenue progression, gross margin stabilization or expansion, reductions in operating expenses, and any strategic partnerships that could catalyze revenue growth or provide non-dilutive funding.